EUCTR2021-001286-20-IT进行中（未招募）1 期
A multi-center, open-label study to determine the dose and safety of oral asciminib in pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), previously treated with one or more tyrosine kinase inhibitors -
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male or female participants:
- •a. Pediatric formulation group: =1 and less than 18 years of age at study entry.
- •b. Adult formulation group: =14 and less than 18 years of age and body weight of = 40 kg at study entry.
- •Participants must meet all of the following laboratory values at the screening visit. In the case where bone marrow blast and promyelocyte counts are available, these will be accepted if done within 56 days prior to the screening visit, to avoid unnecessary repetition of this test.
- •a. 15% blasts in peripheral blood and bone marrow
- •b. < 30% combined blasts plus promyelocytes in peripheral blood and bone marrow
- •c. < 20% basophils in the peripheral blood
- •d. Neutrophils = 1.5 x 10^9/L (or white blood cell (WBC) = 3 x 10^9/L if neutrophils are not available) and platelet count = 100 x 10^9/L
- •e. No evidence of extramedullary leukemic involvement, with the exception of hepatosplenomegaly
- •Prior treatment with a minimum of one TKI.
- •Failure or intolerance to the most recent TKI therapy at the time of screening.
- •Evidence of typical BCR-ABL fusion gene (BCR-ABL1) transcript [e14a2 and/or e13a2] at the time of screening which are amenable to standardized real time quantitative polymerase chain reaction (RQ-PCR) quantification.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Known presence of the T315I mutation prior to study entry.
- •Known second chronic phase of CML after previous progression to AP/BC.
- •Previous treatment with a hematopoietic stem-cell transplantation.
- •Patient planning to undergo allogeneic hematopoietic stem cell transplantation.
- •Cardiac or cardiac repolarization abnormality.
研究者
相似试验
尚未招募
2 期
A multi-center, open-label study to determine the dose and safety of oral asciminib in pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), previously treated with one or more tyrosine kinase inhibitors.NL-OMON54333ovartis1
进行中（未招募）
1 期
Study to determine the dose and safety of asciminib in pediatric patients with chronic myeloid leukemiaPediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), previously treated with one or more tyrosine kinase inhibitorsMedDRA version: 21.0Level: LLTClassification code 10054352Term: Chronic phase chronic myeloid leukemiaSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10060498Term: Juvenile chronic myeloid leukemiaSystem Organ Class: 100000004864MedDRA version: 24.0Level: LLTClassification code 10082178Term: Philadelphia positive chronic myeloid leukemiaSystem Organ Class: 100000004864EUCTR2021-001286-20-GRovartis Pharma AG35
进行中（未招募）
1 期
Study to determine the dose and safety of asciminib in pediatric patients with chronic myeloid leukemiaPediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), previously treated with one or more tyrosine kinase inhibitorsMedDRA version: 21.0Level: LLTClassification code 10054352Term: Chronic phase chronic myeloid leukemiaSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10060498Term: Juvenile chronic myeloid leukemiaSystem Organ Class: 100000004864MedDRA version: 24.0Level: LLTClassification code 10082178Term: Philadelphia positive chronic myeloid leukemiaSystem Organ Class: 100000004864EUCTR2021-001286-20-PLovartis Pharma AG35
进行中（未招募）
1 期
Study to determine the dose and safety of asciminib in pediatric patients with chronic myeloid leukemiaPediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), previously treated with one or more tyrosine kinase inhibitorsMedDRA version: 21.0Level: LLTClassification code 10054352Term: Chronic phase chronic myeloid leukemiaSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10060498Term: Juvenile chronic myeloid leukemiaSystem Organ Class: 100000004864MedDRA version: 24.0Level: LLTClassification code 10082178Term: Philadelphia positive chronic myeloid leukemiaSystem Organ Class: 100000004864EUCTR2021-001286-20-HUovartis Pharma AG35
进行中（未招募）
1 期
Study to determine the dose and safety of asciminib in pediatric patients with chronic myeloid leukemiaPediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), previously treated with one or more tyrosine kinase inhibitorsMedDRA version: 21.0Level: LLTClassification code 10054352Term: Chronic phase chronic myeloid leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10060498Term: Juvenile chronic myeloid leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 24.0Level: LLTClassification code 10082178Term: Philadelphia positive chronic myeloid leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-001286-20-NLovartis Pharma AG35